talfirastide + Placebo
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ischemic Stroke
Conditions
Ischemic Stroke
Trial Timeline
Nov 26, 2023 → Sep 1, 2025
NCT ID
NCT06135103About talfirastide + Placebo
talfirastide + Placebo is a phase 2 stage product being developed by Constant Therapeutics for Ischemic Stroke. The current trial status is unknown. This product is registered under clinical trial identifier NCT06135103. Target conditions include Ischemic Stroke.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06135103 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Ischemic Stroke
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aspirin, Clopidogrel | Yuhan | Pre-clinical | 23 |
| DS-1040b + Placebo | Daiichi Sankyo | Phase 1/2 | 41 |
| DS-1040b + Aspirin | Daiichi Sankyo | Phase 1 | 33 |
| DS1040b + Placebo | Daiichi Sankyo | Pre-clinical | 23 |
| Pharmacological intensification based on olmesartan | Daiichi Sankyo | Phase 2 | 52 |
| Regadenoson | Astellas Pharma | Phase 1 | 33 |
| YM872 (zonampanel), t-PA (alteplase) | Astellas Pharma | Phase 2 | 52 |
| Regadenoson | Astellas Pharma | Approved | 85 |
| ASP2246 | Astellas Pharma | Phase 1/2 | 41 |
| Gadolinium + Adenosine | Astellas Pharma | Phase 2/3 | 65 |
| XY03-EA + XY03-EA Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| Redasemtide + Placebo | Shionogi | Phase 2 | 52 |
| Statin | Shionogi | Approved | 85 |
| fospropofol + propofol | Eisai | Phase 2 | 52 |
| PDE5 Inhibitors | Eli Lilly | Pre-clinical | 23 |
| SB623 Implant (2.5M) + SB623 Implant (5.0M) | Sumitomo Pharma | Phase 2 | 52 |
| Mesenchymal stem cell + Placebo | Rohto Pharmaceutical | Phase 2 | 52 |
| Elezanumab + Placebo | AbbVie | Phase 2 | 52 |
| Balovaptan + Placebo | Roche | Phase 2 | 52 |
| Repatha | Amgen | Approved | 84 |